Top Stories
Cloud breach exposed proprietary information as the drugmaker launches an investigation.
The company is now anticipating revenues of $67.6 billion this year, an increase of $300 million from its prior projection.
Late-stage vaccine misses interim statistical benchmark as biotech trims R&D outlook and awaits key FDA decision on its mRNA flu shot.
The series C financing will go toward its lead Actinium-225 programme, pipeline expansion and manufacturing scale-up.
The miss in the Phase III ZEUS study sent the company's shares down more than 10%.
Conference News
- First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers- On track for interim results reporting in 2H 2026HOUSTON, July 31, 2026 /PRNewswire/ -- FibroBiologics, I...
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax T...
HANGZHOU, China, July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both...
Novel, fast-acting, non-scheduled peptide analgesic addresses the military priority for effective, non-addictive battlefield pain controlKISSIMMEE, Fla.--(BUSINESS WIRE)--PVP Labs, a clinical-stage bi...
The Ask Us Europe survey, led by an academic team in London, and supported by ViiV Healthcare, found 81% of respondents living with HIV recalled having a treatment review, but only 45% had discussed l...
